WO2009125975A3 - 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 - Google Patents

미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 Download PDF

Info

Publication number
WO2009125975A3
WO2009125975A3 PCT/KR2009/001809 KR2009001809W WO2009125975A3 WO 2009125975 A3 WO2009125975 A3 WO 2009125975A3 KR 2009001809 W KR2009001809 W KR 2009001809W WO 2009125975 A3 WO2009125975 A3 WO 2009125975A3
Authority
WO
WIPO (PCT)
Prior art keywords
metformin
mitiglinide
combination
preparing same
ingredient
Prior art date
Application number
PCT/KR2009/001809
Other languages
English (en)
French (fr)
Other versions
WO2009125975A2 (ko
Inventor
한진우
이석
김영훈
Original Assignee
깃세이아쿠힌 고교가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 깃세이아쿠힌 고교가부시키가이샤 filed Critical 깃세이아쿠힌 고교가부시키가이샤
Priority to JP2011503905A priority Critical patent/JP2011516544A/ja
Priority to CN2009801124437A priority patent/CN101990427A/zh
Publication of WO2009125975A2 publication Critical patent/WO2009125975A2/ko
Publication of WO2009125975A3 publication Critical patent/WO2009125975A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 미티글리나이드, 약제학적으로 허용 가능한 그의 염, 또는 그의 수화물; 및 메트포르민, 약제학적으로 허용 가능한 그의 염, 또는 그의 수화물을 포함하는 복합제제로서, 상기에서 미티글리나이드 성분은, 메트포르민 성분에 의하여 간섭됨이 없이, 미티글리나이드 단일제제의 용출 패턴과 동등 또는 유사한 용출 패턴을 나타내며, 메트포르민 성분 또한 메트포르민 단일제제의 용출 패턴과 동등 또는 유사한 용출 패턴을 갖는 것을 특징으로 하는 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법에 관한 것이다.
PCT/KR2009/001809 2008-04-08 2009-04-08 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 WO2009125975A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2011503905A JP2011516544A (ja) 2008-04-08 2009-04-08 ミチグリニドおよびメトホルミンの複合製剤並びにその製造方法
CN2009801124437A CN101990427A (zh) 2008-04-08 2009-04-08 米格列奈及二甲双胍的复合制剂及其制造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080032673A KR101512386B1 (ko) 2008-04-08 2008-04-08 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법
KR10-2008-0032673 2008-04-08

Publications (2)

Publication Number Publication Date
WO2009125975A2 WO2009125975A2 (ko) 2009-10-15
WO2009125975A3 true WO2009125975A3 (ko) 2009-12-03

Family

ID=41162388

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001809 WO2009125975A2 (ko) 2008-04-08 2009-04-08 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법

Country Status (5)

Country Link
JP (1) JP2011516544A (ko)
KR (1) KR101512386B1 (ko)
CN (1) CN101990427A (ko)
TW (1) TW200946111A (ko)
WO (1) WO2009125975A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CA2780939C (en) * 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Bilayer tablet formulations
CN108354930A (zh) 2010-05-11 2018-08-03 詹森药业有限公司 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂
CN102970981A (zh) * 2010-07-06 2013-03-13 詹森药业有限公司 糖尿病协同治疗制剂
KR101441355B1 (ko) * 2013-05-29 2014-09-17 주식회사 다림바이오텍 레파글리니드 및 메트포르민을 함유하는 이층정 및 그의 제조방법
CN110840855B (zh) * 2019-11-27 2022-04-12 哈尔滨珍宝制药有限公司 依托考昔片及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686337B2 (en) * 2000-10-30 2004-02-03 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising anti-diabetic and anticonvulsant agents
KR20060051510A (ko) * 2004-09-23 2006-05-19 주식회사 한독약품 경구투여를 위한 당뇨병 치료용 약제학적 복합제제
KR20060077812A (ko) * 2004-12-31 2006-07-05 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
WO2007043853A1 (es) * 2005-10-12 2007-04-19 World-Trade Import-Export, Wtie, Ag. Composiciones farmacéuticas que comprenden sustan- cias antidiabéticas combinadas para su uso en diabete mellitus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686337B2 (en) * 2000-10-30 2004-02-03 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising anti-diabetic and anticonvulsant agents
KR20060051510A (ko) * 2004-09-23 2006-05-19 주식회사 한독약품 경구투여를 위한 당뇨병 치료용 약제학적 복합제제
KR20060077812A (ko) * 2004-12-31 2006-07-05 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
WO2007043853A1 (es) * 2005-10-12 2007-04-19 World-Trade Import-Export, Wtie, Ag. Composiciones farmacéuticas que comprenden sustan- cias antidiabéticas combinadas para su uso en diabete mellitus

Also Published As

Publication number Publication date
JP2011516544A (ja) 2011-05-26
WO2009125975A2 (ko) 2009-10-15
KR20090107262A (ko) 2009-10-13
TW200946111A (en) 2009-11-16
KR101512386B1 (ko) 2015-04-17
CN101990427A (zh) 2011-03-23

Similar Documents

Publication Publication Date Title
DK3872059T3 (en) Process for the preparation of 2,3,3,3 tetrahydrofluoropropene
WO2009084024A3 (en) A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
WO2008070072A3 (en) Carvedilol forms, compositions, and methods of preparation thereof
WO2009025873A3 (en) Processes for the preparation of crystalline forms a, b and pure crystalline form a of erlotinib hcl
HK1201822A1 (en) Process for the preparation of 5,6-dihydro-1h-pyridin-2-one compounds 56--1h--2-
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
IL187235A0 (en) 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
WO2009066315A3 (en) Sustained release compositions of trimetazidine and process for preparation thereof
WO2009125975A3 (ko) 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법
WO2006081515A3 (en) Duloxetine hydrochloride polymorphs
WO2010070677A3 (en) A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2008051539A3 (en) Processes for preparing palonosetron salts
WO2007132354A3 (en) Process for preparing voriconazole, new polymorphic form of intermediate thereof, and uses thereof
PL1989182T3 (pl) Postać krystaliczna soli peryndoprylu z argininą, sposób jej wytwarzania i kompozycje farmaceutyczne ją zawierające
HK1108580A1 (en) A process for the preparation of [1,4,5]-oxadiazepine derivatives
WO2007119120A3 (en) Crystalline polymorphic forms of olopatadine hydrochloride and processes for their preparation
WO2008117305A3 (en) A novel process for preparing pregabalin and its acid addition salts
WO2008009970A3 (en) Process for the preparation of montelukast
WO2010079045A3 (en) Crystalline salt forms of flibanserine
WO2010046932A3 (en) Extended release pharmaceutical composition of minocycline and process thereof
WO2007098273A3 (en) Novel crystalline forms of armodafinil and preparation thereof
WO2008034912A3 (en) Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof
WO2011135586A3 (en) Process for the preparation of chiral beta amino carboxamide derivatives
WO2009025792A3 (en) Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980112443.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09731387

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011503905

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09731387

Country of ref document: EP

Kind code of ref document: A2